Is anonymity the real issue here?
Fully-anonymised data on this scale must have considerable commercial value to pharma research interested in such things as the prevalence of genetic patterns. If it's explicitly in the public domain, that's fine. If not, then industrial espionage becomes an obvious issue.
IP companies specialising in patents could be a prime suspect here.